Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Amgen other Products (Segment Note 2 Aggregate) — Worldwide product sales ($M) ($M)
Form 10-Q / 10-K Note 2 Segment Reporting & MD&A
Latest, FY2025
7,263
Period ended Dec 31, 2025
Change on a year earlier
+29.0%
5,630 in FY2024
History
13 years
Since FY2013
Sources
8
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Other Products (Segment Note 2 Aggregate) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 7,263 | +29.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 5,630 | +19.9% | Form 10-K (filed 2026-02-13) ↗ |
| FY2023 | Dec 31, 2023 | 4,696 | -7.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2022 | Dec 31, 2022 | 5,050 | -11.6% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 5,710 | +6.3% | Form 10-K (filed 2024-02-14) ↗ |
| FY2020 | Dec 31, 2020 | 5,374 | +13.3% | Form 10-K (filed 2023-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 4,743 | -14.9% | Form 10-K (filed 2022-02-16) ↗ |
| FY2018 | Dec 31, 2018 | 5,572 | +63.0% | Form 10-K (filed 2021-02-09) ↗ |
| FY2017 | Dec 31, 2017 | 3,418 | +8.2% | Form 10-K (filed 2019-02-13) ↗ |
| FY2016 | Dec 31, 2016 | 3,158 | +68.2% | Form 10-K (filed 2019-02-13) ↗ |
| FY2015 | Dec 31, 2015 | 1,877 | +24.0% | Form 10-K (amgn-12312015x10k.htm, filed 2016-02-16) ↗ |
| FY2014 | Dec 31, 2014 | 1,514 | +33.4% | Form 10-K (amgn-12312015x10k.htm, filed 2016-02-16) ↗ |
| FY2013 | Dec 31, 2013 | 1,135 | – | Form 10-K (amgn-12312015x10k.htm, filed 2016-02-16) ↗ |
Breakdown
What makes up other products (segment note 2 aggregate) — worldwide product sales ($m)
- Other Products (Segment Note 2 Aggregate) — U.S. product sales ($M)5,437 · FY2025
- Other Products (Segment Note 2 Aggregate) — Rest of World (ROW) product sales ($M)1,826 · FY2025
- Biosimilars Included in Other Product Sales — Worldwide ($M)683 · FY2025
- Other Residual Products (8-K Schedule) — Worldwide ($M)1,311 · FY2025
Cite this data
StockData. (2026). Amgen Other Products (Segment Note 2 Aggregate) — Worldwide product sales ($M) ($M), annual FY2013–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_other_ww
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.